home All News open_in_new Full Article

China’s SciNeuro, Novartis sign US$1.7 billion licensing deal to develop Alzheimer’s drugs

A partnership between China’s SciNeuro Pharmaceuticals and Swiss pharmaceutical giant Novartis on Monday has revived hopes for treating Alzheimer’s disease. The deal, worth nearly US$1.7 billion, grants Novartis exclusive worldwide rights to develop and commercialise SciNeuro’s antibody candidates to develop drugs for the progressive brain disease. SciNeuro’s novel amyloid beta targeted antibody programme leverages proprietary blood-brain barrier shuttle technology to help more of the drug cross...


today 4 d. ago attach_file Economics

attach_file Politics
attach_file Politics
attach_file Politics
attach_file Events
attach_file Events
attach_file Politics
attach_file Society
attach_file Politics
attach_file Politics
attach_file Politics
attach_file Politics
attach_file Politics
attach_file Economics
attach_file Politics
attach_file Politics
attach_file Events
attach_file Politics
attach_file Politics
attach_file Politics
attach_file Politics


ID: 1446736835
Add Watch Country

arrow_drop_down